AM

Amicogen, Inc.

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.

092040 | KO

Overview

Corporate Details

ISIN(s):
KR7092040005
LEI:
Country:
South Korea
Address:
경상남도 진주시 문산읍 월아산로950번길 14-10 아미코젠 문산 1공장, 진주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amicogen, Inc. is an industrial biotechnology company founded in 2000 that specializes in the research, development, and production of special enzymes and other bio-new materials. Leveraging its core enzyme technology, the company provides solutions for the pharmaceutical and healthcare sectors. Its business areas include developing functional ingredients for health and nutrition through its KNUTRA brand, producing cell culture media, and offering Contract Development and Manufacturing Organization (CDMO) services for the bioprocess industry. Amicogen is focused on creating sustainable value for human health and the environment through continuous innovation and R&D.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-09-18 00:00
Share Issue/Capital Change
전환가액의조정 (제4회차)
Korean 10.6 KB
2025-09-17 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
불성실공시법인지정 (공시변경)
Korean 6.0 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.3 MB
2025-08-11 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제6회차 CB)
Korean 5.6 KB
2025-08-01 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 49.8 KB
2025-07-30 00:00
Legal Proceedings Report
소송등의판결ㆍ결정(일정금액이상의청구) (대여금 청구-취하)
Korean 7.0 KB
2025-07-28 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(일정금액이상의청구)
Korean 7.3 KB
2025-07-25 00:00
Regulatory News Service
불성실공시법인지정예고
Korean 4.9 KB
2025-07-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-25 00:00
Regulatory News Service
[기재정정]신규시설투자등
Korean 12.1 KB
2025-05-23 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.9 KB
2025-05-14 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB

Automate Your Workflow. Get a real-time feed of all Amicogen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amicogen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amicogen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

YD Bio Ltd Logo
Developing blood-based cancer detection and regenerative therapies for biopharma partners.
United States of America
YDES
YUHAN CORPORATION Logo
A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.
South Korea
000100
YUKI GOSEI KOGYO CO.,LTD. Logo
Manufactures fine chemicals, amino acids, and APIs via organic synthesis for global industries.
Japan
4531
Zai Lab Ltd Logo
Global biopharma firm developing therapies for oncology, immunology, neuroscience & infectious diseases.
United States of America
ZLAB
Zealand Pharma Logo
Developing innovative peptide medicines for metabolic and inflammatory diseases.
Denmark
ZEAL
Zelluna ASA Logo
Developing off-the-shelf TCR-NK cell therapies to treat patients with solid cancers.
Norway
ULTI
Zenas BioPharma, Inc. Logo
Clinical-stage biopharma developing immunology-based therapies for autoimmune diseases.
United States of America
ZBIO
Zentalis Pharmaceuticals, Inc. Logo
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
United States of America
ZNTL
Zentiva 2 Logo
European provider of high-quality, affordable generic and over-the-counter medicines.
Slovakia
SKF

Talk to a Data Expert

Have a question? We'll get back to you promptly.